Independently owned:

The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Forbion is owned by its Partners.

Innovative specialist team:

The Forbion team focuses on life sciences and bio-medical technology, developing world-class drugs and technologies. The team is a talented and balanced team of 11 professionals with financial, clinical, scientific and operational backgrounds. As at the end of 2016, Forbion made 56 investments in EU and US with focus on unmet medical needs. They realized 26 exits and quoted 4 companies.

Strong infrastructure:

Forbion Capital Partners has offices in the Netherlands, and Germany, and representatives in US and Israel.
The team manages over €540 mln, split between 5 active funds and comprising some 28 promising portfolio companies. Forbion co-manages Biogeneration Ventures, an early stage-stage fund focused on academic spin-outs and seed investments in the Netherlands.